Use of monomycolyl glycerol (MMG) as an adjuvant
    1.
    发明授权
    Use of monomycolyl glycerol (MMG) as an adjuvant 有权
    使用单螺旋甘油(MMG)作为佐剂

    公开(公告)号:US08563009B2

    公开(公告)日:2013-10-22

    申请号:US12666102

    申请日:2008-06-26

    IPC分类号: A61K31/726

    摘要: Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.

    摘要翻译: 在这里,我们将MMG及其α-和酮环酸衍生物鉴定为能够以极低剂量刺激和激活人类DC的牛分枝杆菌BCG(哥本哈根)的高度生物活性脂质。 除了它们作为人类DC的免疫刺激剂的直接作用之外,我们还展示了其在开发适合人类给药的新一代佐剂中的用途。 此外,我们还确定了一些在癌症治疗中具有巨大潜力的高活性合成MMG类似物,以及针对传染病和类似阿尔茨海默病的疾病的疫苗佐剂。

    Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines
    3.
    发明授权
    Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines 有权
    用于免疫组合物和疫苗的脂质体和分枝杆菌脂质的佐剂组合

    公开(公告)号:US08241610B2

    公开(公告)日:2012-08-14

    申请号:US13083385

    申请日:2011-04-08

    IPC分类号: A61K9/127 A61B5/055

    摘要: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.

    摘要翻译: 本发明提供了由表面活性剂,即二甲基十八烷基溴化铵/氯化物(DDA)和牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。 总脂质提取物包含非极性脂质,极性脂质和具有中性极性的脂质,其中发现非极性脂质诱导最强大的免疫应答。 总脂质可以用氯仿/甲醇萃取,并在加入表面活性剂之前再溶解在水中。 该制剂可用于诱导哺乳动物中突出的细胞介导的免疫应答以抵抗病原体,或用作癌症治疗。

    MODIFIED CATIONIC LIPOSOME ADJUVANS
    4.
    发明申请
    MODIFIED CATIONIC LIPOSOME ADJUVANS 审中-公开
    改性阳离子脂质体

    公开(公告)号:US20110287087A1

    公开(公告)日:2011-11-24

    申请号:US13129079

    申请日:2009-11-10

    摘要: The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of anti-bodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.

    摘要翻译: 本发明涉及疫苗与包含阳离子脂质体的佐剂的疫苗,其中中性脂质已经引入脂质体中以改变凝胶 - 液相转变,从而改变IgG亚型应答并增强脂质体佐剂的CD8应答。 该技术可用于增加IgG2抗体的产生。 已经显示这种亚型抗体(对应于人类中IgG3的小鼠中的IgG2)选择性地与先天免疫细胞表面上的Fc激活受体结合,导致增强的促炎反应,从而更高效的免疫应答 动物模型中的保护 疟疾和衣原体。 选择性地引起更高水平的IgG2抗体的佐剂的使用将改善疫苗的效果,例如, 针对细胞内感染。 此外,该技术可用于诱导CD8应答,其已被报道以改善疫苗对例如抗体的作用。 HPV,HIV,流感和癌症。

    ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES
    5.
    发明申请
    ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES 有权
    用于免疫组合物和疫苗的脂质体和肌醇脂的补充剂组合

    公开(公告)号:US20110250224A1

    公开(公告)日:2011-10-13

    申请号:US13083385

    申请日:2011-04-08

    摘要: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.

    摘要翻译: 本发明提供了由表面活性剂,即二甲基十八烷基溴化铵/氯化物(DDA)和牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。 总脂质提取物包含非极性脂质,极性脂质和具有中性极性的脂质,其中发现非极性脂质诱导最强大的免疫应答。 总脂质可以用氯仿/甲醇萃取,并在加入表面活性剂之前再溶解在水中。 该制剂可用于诱导哺乳动物中突出的细胞介导的免疫应答以抵抗病原体,或用作癌症治疗。